Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Oncology Clinical Research GLP-1 Drugs Market Trends Regulatory Approval Obesity Treatment Obesity Treatments Market Competition Immunology Regulatory Affairs Generic Drugs Monoclonal Antibodies Cancer Treatment FDA Regulations Market Performance Research and Development Manufacturing Pricing Strategies Autoimmune Diseases Market Dynamics Weight Loss Medications Alzheimer's Disease Injectable Medications Market Analysis GLP-1 Treatments Obesity Drugs Weight Management Therapeutics FDA Approvals Rare Diseases Sales Performance AI in Healthcare Biotechnology Neurology Patent Expiration Preventive Medicine Oncology Drugs Antibiotics Weight-loss Drugs Psoriasis Treatments Weight Loss Treatments Cancer Treatments AI Applications Patent Issues Pain Management Mental Health Treatments COVID-19 Vaccines Diabetes Treatment Cystic Fibrosis Treatments Pipeline Weight-Loss Drugs Duchenne Muscular Dystrophy GLP-1 Medications Injectable Treatments Generic Medications GLP-1 Agonists Gene Editing Diabetes Treatments Metabolic Diseases AI in Medicine Investigational Drugs Regulatory Approvals Genetic Medicine HIV Treatment Active Ingredients FDA Approval Process FDA Designations FDA Approval Antiviral Drugs Generic Medicines Eli Lilly and Company Patent Protection Acquisitions Vaccines Chronic Disease Management Innovative Therapies Antibody Drug Conjugates Targeted Therapy Innovative Medicines Biosimilars Antimalarial Drugs Market Launches GLP-1 Therapies Gene Therapy Imdelltra Psychedelics Alzheimer's Treatment Anti-Obesity Drugs Formulation Treatment Options GLP-1RA Peptide Therapy Immunotherapy Mental Health Brain Health HIV Medications Pfizer Inc. OXBRYTA

Securities Suit Alleges Unicycive Hid Manufacturing Oversight That Could Delay OLC Approval

Plaintiff firms are soliciting investors to join the case or seek lead‑plaintiff status before the November 2, 2026 deadline.

Court Rules Liquidia’s Yutrepia Infringes United Therapeutics Patent

Moderna and Merck Report Positive Phase 3 Topline for Personalized Melanoma Vaccine

Iambic Therapeutics Files for Nasdaq IPO to Fund AI Cancer Pipeline

Novo Nordisk Teams With Anthropic to Test Claude for Drug Discovery

Novartis’ Pelacarsen Fails Phase 3 Outcome Trial

Amgen's Cash Strength Versus Moderna's mRNA Pivot

Novartis Faces Investor Backlash After Second Late‑Stage Trial Failure

iShares' Healthcare and Pharmaceuticals ETFs Share Fees as Fidelity's FHLC Undercuts Rivals

Eli Lilly Trades Near $1,160 as GLP-1 Sales and FDA Cardio Approval Drive Valuation

FDA Expands Approval of J&J’s Imaavy to Treat Warm Autoimmune Hemolytic Anemia

GLP-1 Drugs Reshape Obesity Care

BioMarin to Buy Alesta for $275 Million to Add Oral HPP Drug

Capricor Seeks New FDA Path for Duchenne Drug After 9–3 Advisory Vote

Bristol Myers Squibb to Build $2.3 Billion Modular Manufacturing Campus in Houston

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Lilly Pulls Further Ahead in GLP-1 Race After Blowout Quarter

Reuters Says There Were No AstraZeneca‑Bristol Myers Merger Talks

BioCryst Cuts Internal Discovery After Q2 ORLADEYO Gains and Pediatric Rollout

Baron Capital Reaffirms Long-Term Bullish View on Health Care and Repositions Fund